title: Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
authors.forename: Masanori
authors.initials: M
authors.lastname: Yoshida
authors.forename: Masato
authors.initials: M
authors.lastname: Asai
authors.forename: Misaki
authors.initials: M
authors.lastname: Miyata
authors.forename: Koichiro
authors.initials: K
authors.lastname: Ogawa
authors.forename: Harumi
authors.initials: H
authors.lastname: Maeda
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Oiso
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004359:Drug Therapy, Combination; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D054795:Incretins / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000187:drug effects*; D000069450:Liraglutide; D008297:Male; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D054795:Incretins; D007330:Insulin Antibodies; D013453:Sulfonylurea Compounds; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1